The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
Erada Technology Alliance said the Global Health Innovative Technology Fund grant facilitates production, testing, and validation trials for the rapid test for malaria.
The startup holds an exclusive license from Johns Hopkins University and intends to launch its test in time for World Malaria Day in April 2020.
The test uses unique PCR chemistries as well as a streamlined sample prep method to detect resistance mutations without DNA extraction.
PATH is using the tool to benchmark RDTs for several diagnostic companies and help them understand if their products are meeting competitive performance standards.
The firm is working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support early detection of tropical diseases.
The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The firm's CTO Sarah Levy said the Series C funding will enable it to expand R&D activities to develop applications beyond complete blood counts.